Oncolytics Biotech financials
$0.6745+1.73%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q1 '16 Mar 31 | Q4 '15 Dec 31 | Q3 '15 Sep 30 | Q2 '15 Jun 30 | Q1 '15 Mar 31 | Q4 '14 Dec 31 | Q3 '14 Sep 30 | Q2 '14 Jun 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | — | — | — | — | — | — | — | — |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$9.4M | -$9.3M | -$4.7M | -$5.0M | -$4.1M | -$3.5M | -$2.9M | -$3.9M | -$3.6M | -$3.8M | -$4.7M | -$4.8M |
| Net income | -$9.4M | -$9.2M | -$5.3M | -$4.7M | -$4.0M | -$3.5M | -$2.8M | -$3.9M | -$3.6M | -$3.8M | -$4.6M | -$4.7M |
| Net margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-0.08 | $-0.08 | $-0.06 | $-0.06 | $-0.29 | $-0.03 | $-0.19 | $-0.29 | $-0.38 | $-0.04 | $-0.48 | $-0.48 |
| EBITDA | -$9.4M | -$9.3M | -$4.6M | -$5.0M | -$4.0M | -$3.5M | -$2.8M | -$3.8M | -$3.6M | -$3.8M | -$4.6M | -$4.7M |
| Operating cash flow | -$8.1M | -$7.3M | -$4.1M | -$4.7M | -$3.0M | -$4.3M | -$2.9M | -$5.1M | -$2.7M | -$3.3M | -$4.4M | -$5.8M |
| Free cash flow | -$8.1M | -$7.3M | -$4.1M | -$4.7M | — | -$4.4M | -$2.9M | -$5.1M | -$2.8M | -$3.3M | -$4.5M | -$5.8M |
| Diluted shares | 119.7M | 112.3M | 91.0M | 84.6M | 12.4M | 12.5M | 12.4M | 12.1M | 10.5M | 87.9M | 9.3M | 9.1M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $4.1M | $5.5M | $5.2M | $11.1M | $26.3M | $8.6M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $15.1M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $7.7M | $8.2M | $7.6M | $13.4M | $29.3M | $27.5M |
| Total liabilities | $13.8M | $13.3M | $11.4M | $10.1M | $8.5M | $8.0M |
| Shareholders' equity | -$6.2M | -$5.1M | -$3.8M | $3.3M | $20.8M | $19.5M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology